凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2014年第一季度报告全文

公告日期 2014-04-26
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2014 年第一季度报告全文




华兰生物工程股份有限公司

   2014 年第一季度报告




      2014 年 04 月




                                                              1
                                      华兰生物工程股份有限公司 2014 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管

人员)王建体声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                    2
                                                                 华兰生物工程股份有限公司 2014 年第一季度报告全文




                              第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                                                                            本报告期比上年同期增减
                                            本报告期                   上年同期
                                                                                                    (%)

营业收入(元)                                  278,440,387.76             292,469,257.21                     -4.8%

归属于上市公司股东的净利润(元)                174,398,390.97             130,990,154.36                   33.14%

归属于上市公司股东的扣除非经常性损
                                                132,414,582.71             126,130,587.15                    4.98%
益的净利润(元)

经营活动产生的现金流量净额(元)                103,989,566.97             111,949,445.95                    -7.11%

基本每股收益(元/股)                                   0.3002                    0.2273                    32.07%

稀释每股收益(元/股)                                   0.3002                    0.2273                    32.07%

加权平均净资产收益率(%)                                5.51%                     4.92%                     0.59%

                                                                                            本报告期末比上年度末增
                                           本报告期末                  上年度末
                                                                                                    减(%)

总资产(元)                                  3,711,645,711.45           3,643,315,938.55                    1.88%

归属于上市公司股东的净资产(元)              3,251,808,959.72           3,077,410,568.75                    5.67%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                            单位:元

                           项目                            年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                     36,977.83

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                       34,794,794.61
一标准定额或定量享受的政府补助除外)

除上述各项之外的其他营业外收入和支出                                      -32,858.47

其他符合非经常性损益定义的损益项目                                     14,929,801.64

减:所得税影响额                                                        7,032,407.35

       少数股东权益影响额(税后)                                         712,500.00

合计                                                                   41,983,808.26                --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用

                                                                                                                      3
                                                                  华兰生物工程股份有限公司 2014 年第一季度报告全文


二、报告期末股东总数及前十名股东持股情况表

                                                                                                               单位:股

报告期末股东总数                                                                                                52,345

                                                 前 10 名股东持股情况

                                                                                持有有限售          质押或冻结情况
                                                      持股比例
               股东名称                股东性质                   持股数量      条件的股份
                                                       (%)                                   股份状态        数量
                                                                                  数量

                                      境内非国有
新乡市华兰生物技术有限公司                               17.68%   102,723,822              0
                                      法人

                                      境内非国有
新乡市金康生物科技开发有限公司                           15.14%    87,961,115              0
                                      法人

香港科康有限公司                      境外法人           13.24%    76,889,088              0

                                      境内非国有
新乡市世辰生物技术有限公司                                3.66%    21,247,640              0
                                      法人

中国工商银行-汇添富均衡增长股票型
                                      其他                2.29%    13,323,847              0
证券投资基金

中国人民财产保险股份有限公司-传统
                                      其他                1.39%     8,077,136              0
-普通保险产品

兴业银行股份有限公司-兴全趋势投资
                                      其他                1.35%     7,831,157              0
混合型证券投资基金

中国工商银行-汇添富医药保健股票型
                                      其他                0.87%     5,030,689              0
证券投资基金

华夏银行股份有限公司-德盛精选股票
                                      其他                 0.6%     3,500,000              0
证券投资基金

中国民生银行-银华深证 100 指数分级
                                      其他                0.58%     3,362,935              0
证券投资基金

                                         前 10 名无限售条件股东持股情况

                                                                                                股份种类
                   股东名称                          持有无限售条件股份数量
                                                                                         股份种类           数量

新乡市华兰生物技术有限公司                                              102,723,822 人民币普通股            102,723,822

新乡市金康生物科技开发有限公司                                           87,961,115 人民币普通股             87,961,115

香港科康有限公司                                                         76,889,088 人民币普通股             76,889,088

新乡市世辰生物技术有限公司                                               21,247,640 人民币普通股             21,247,640

中国工商银行-汇添富均衡增长股票型证券投
                                                                         13,323,847 人民币普通股             13,323,847
资基金

中国人民财产保险股份有限公司-传统-普通
                                                                          8,077,136 人民币普通股              8,077,136
保险产品


                                                                                                                          4
                                                               华兰生物工程股份有限公司 2014 年第一季度报告全文


兴业银行股份有限公司-兴全趋势投资混合型
                                                                       7,831,157 人民币普通股        7,831,157
证券投资基金

中国工商银行-汇添富医药保健股票型证券投
                                                                       5,030,689 人民币普通股        5,030,689
资基金

华夏银行股份有限公司-德盛精选股票证券投
                                                                       3,500,000 人民币普通股        3,500,000
资基金

中国民生银行-银华深证 100 指数分级证券投资
                                                                       3,362,935 人民币普通股        3,362,935
基金

                                              上述第一、二、三、四股东存在关联关系,属于一致行动人。中国工商银
                                              行-汇添富均衡增长股票型证券投资基金和中国工商银行-汇添富医药
上述股东关联关系或一致行动的说明
                                              保健股票型证券投资基金同为汇添富基金管理有限公司旗下基金,未知其
                                              他股东之间是否存在关联关系,是否属于一致行动人。

前十大股东参与融资融券业务股东情况说明(如
                                              不存在
有)

公司股东在报告期内是否进行约定购回交易
□ 是 √ 否




                                                                                                                 5
                                                                 华兰生物工程股份有限公司 2014 年第一季度报告全文




                                            第三节 重要事项

一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因

1、应收票据期末较期初减少41.78%,主要原因是公司票据背书或到期结算所致。
2、其他流动资产期末较期初增加43.31%,主要原因是公司理财产品增加所致。
3、短期借款期末较期初减少9,000万元,主要原因是本公司之子公司华兰生物工程重庆有限公司归还到期贷款所致。
4、预收账款期末较期初减少52.19%,主要原因是预收货款已发货并确认收入所致。
5、其他应付款期末较期初减少39.8%,主要原因是本公司之子公司华兰生物工程重庆有限公司保证金结算所致。
6、营业成本报告期较上年同期减少38.6%,主要原因一是营业收入较上年同期减少,相应营业成本减少;二是上年同期本
公司之子公司华兰生物工程重庆有限公司投产初期产品成本较高。
7、营业税金及附加报告期较上年同期增加40.59%,主要原因是本公司之子公司华兰生物工程重庆有限公司上年同期执行增
值税税率17%,抵扣进项税额,而本报告期增值税税率按6%简易征收,应纳增值税增加,相应附征增加所致。
8、销售费用报告期较上年同期增加115.83%,主要原因是公司加大市场推广力度,相应销售费用增加所致。
9、管理费用报告期较上年同期增加30.63%,主要原因是公司研发费用增加所致。
10、财务费用报告期较上年同期增加34.89%,主要原因是存款利息收入减少所致。
11、投资收益报告期较上年同期增加204.46%,主要原因是理财收益增加所致。
12、营业外收入报告期较上年同期增加3,451万元,主要原因是本报告期收到政府补助较上年同期增加所致。
13、所得税费用本报告期较上年同期增加114.46%,主要原因一是本公司收到政府补助3,400万,利润总额增加,相应所得税
费用增加所致。
14、取得投资收益所收到的现金报告期较上年同期增加210.82%,主要原因是报告期内银行理财产品收益增加所致。
15、取得借款收到的现金报告期较上年同期减少1.4亿元,主要原因是本公司之子公司华兰生物工程重庆有限公司归还到期
贷款所致。


二、重要事项进展情况及其影响和解决方案的分析说明



             重要事项概述                             披露日期                      临时报告披露网站查询索引


三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项

     承诺事项    承诺方                       承诺内容                    承诺时间      承诺期限        履行情况

股改承诺         不适用 不适用                                                        不适用       不适用

收购报告书或权
益变动报告书中 不适用 不适用                                                          不适用       不适用
所作承诺

资产重组时所作
                 不适用 不适用                                                        不适用       不适用
承诺

首次公开发行或 实际控 为避免同业竞争引起的损害本公司及其他股东利         2004 年 06                正在严格履行
                                                                                      长期
再融资时所作承 制人         益,本公司实际控制人安康先生承诺:“作为本公 月 25 日                  中



                                                                                                                   6
                                                                  华兰生物工程股份有限公司 2014 年第一季度报告全文


诺                        司实际控制人期间,不在与本公司构成同业竞争的
                          其他公司任职,在其经营业务中将不会利用其在本
                          公司及本公司股东中的地位从事任何有损本公司
                          及其他股东利益的行为。”

                          公司未来三年(2012-2014 年)的具体股东回报规
                          划:1、公司可以采取现金、股票、现金与股票相
                          结合或者法律、法规允许的其他方式分配利润。2、
                          根据《公司法》等有关法律法规及《公司章程》的
                          规定,在公司盈利且现金能够满足公司持续经营和
                          长期发展、符合现金分红条件的前提下,2012-2014
                          年每年以现金方式分配的利润应不低于当年实现
                          的可分配利润的 10%,且连续三年内以现金方式累
                          计分配的利润不少于该三年实现的年均可分配利
                                                                           2012 年 08                    正在严格履行
                 董事会 润的 30%。 3、未来三年(2012-2014 年)公司原                    2012-2014 年度
                                                                           月 29 日                      中
                          则上每年度进行一次现金分红,公司董事会可以根
                          据公司盈利情况及资金需求状况提议公司进行中
                          期现金分红。 4、未来三年(2012-2014)公司可
                          以根据累计可供分配利润、公积金及现金流状况,
                          在保证最低现金分红比例和公司股本规模合理的
                          前提下,为保持股本扩张与业绩增长相适应,公司
                          可以采取股票股利方式进行利润分配,具体分红比
其他对公司中小            例由公司董事会审议通过后,并提交股东大会审议
股东所作承诺              决定。

                 实际控 实际控制人安康先生承诺:自限制性股票授予日起 2013 年 05 2016 年 8 月 27 正在严格履行
                 制人     三十六个月内不转让获授限制性股票                 月 27 日     日               中

                          (1)激励对象所获授的限制性股票及相应的股票
                          股利锁定期满在二级市场上出售或以其他方式转
                          让时,应当符合《公司法》、《证券法》、《上市规则》
                          等法律法规以及华兰生物公司治理文件的相关规
                          定。(2)公司董事、高管所获授的限制性股票及股
                 除实际
                          票股利在解锁期内出售应遵循《公司法》、《证券
                 控制人
                          法》、《上市规则》的限售规定。即:作为公司董事、2013 年 05 2016 年 8 月 27 正在严格履行
                 外的其
                          高管的激励对象每年转让其持有的华兰生物股票       月 27 日     日               中
                 他激励
                          不得超过其所持有的公司股票总数的百分之二十
                 对象
                          五,在离职后六个月内不得转让其所有的公司股
                          份。在申报离任六个月后的十二月内通过证券交易
                          所挂牌交易出售本公司股票数量占其所持有本公
                          司股票总数(包括有限售条件和无限售条件的股
                          份)的比例不得超过 50%。

承诺是否及时履
                 是


未完成履行的具
                 无
体原因及下一步


                                                                                                                        7
                                                                  华兰生物工程股份有限公司 2014 年第一季度报告全文


计划(如有)


四、对 2014 年 1-6 月经营业绩的预计

2014 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2014 年 1-6 月归属于上市公司股东的净利润变
                                                                         10%    至                              30%
动幅度(%)

2014 年 1-6 月归属于上市公司股东的净利润变
                                                                    25,409.58   至                           30,029.5
动区间(万元)

2013 年 1-6 月归属于上市公司股东的净利润(万
                                                                                                         23,099.62
元)

                                               公司预计 2014 年 1-6 月份归属于上市公司股东的净利润同比增加
业绩变动的原因说明                             10%-30%,主要原因一是公司血液制品收入较上年同期增长;二是收到政
                                               府补贴较上年同期增加。




                                                                                                                        8
                                                         华兰生物工程股份有限公司 2014 年第一季度报告全文




                                     第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:华兰生物工程股份有限公司
                                                                                                    单位:元

                 项目                    期末余额                                期初余额

流动资产:

    货币资金                                         755,564,321.25                         1,035,311,503.25

    结算备付金

    拆出资金

    交易性金融资产

    应收票据                                          36,484,226.66                           62,661,861.40

    应收账款                                         181,282,540.74                          170,710,176.97

    预付款项                                         100,956,213.92                           82,845,091.05

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息

    应收股利

    其他应收款                                         3,173,466.64                            2,509,171.20

    买入返售金融资产

    存货                                             398,314,475.37                          342,588,796.14

    一年内到期的非流动资产

    其他流动资产                                     943,000,000.00                          658,000,000.00

流动资产合计                                        2,418,775,244.58                        2,354,626,600.01

非流动资产:

    发放委托贷款及垫款

    可供出售金融资产

    持有至到期投资

    长期应收款

    长期股权投资                                      39,821,531.35                           40,094,602.70



                                                                                                               9
                              华兰生物工程股份有限公司 2014 年第一季度报告全文


    投资性房地产

    固定资产              786,660,448.32                        807,062,269.33

    在建工程              216,129,514.67                        184,340,318.65

    工程物资

    固定资产清理

    生产性生物资产          1,035,890.27                          1,961,961.02

    油气资产

    无形资产              134,489,257.67                        135,855,861.74

    开发支出

    商誉

    长期待摊费用            3,328,883.00                          3,444,439.00

    递延所得税资产         11,404,941.59                         15,929,886.10

    其他非流动资产        100,000,000.00                        100,000,000.00

非流动资产合计           1,292,870,466.87                     1,288,689,338.54

资产总计                 3,711,645,711.45                     3,643,315,938.55

流动负债:

    短期借款               60,000,000.00                        150,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    交易性金融负债

    应付票据

    应付账款               87,590,488.88                         83,051,891.60

    预收款项                5,679,042.70                         11,877,134.01

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬              710,641.99                           264,598.18

    应交税费               38,539,834.26                         29,125,221.57

    应付利息

    应付股利

    其他应付款             35,055,073.51                         58,231,319.85

    应付分保账款

    保险合同准备金

    代理买卖证券款



                                                                            10
                                                               华兰生物工程股份有限公司 2014 年第一季度报告全文


     代理承销证券款

     一年内到期的非流动负债

     其他流动负债

流动负债合计                                               227,575,081.34                          332,550,165.21

非流动负债:

     长期借款

     应付债券

     长期应付款

     专项应付款

     预计负债

     递延所得税负债

     其他非流动负债

非流动负债合计

负债合计                                                   227,575,081.34                          332,550,165.21

所有者权益(或股东权益):

     实收资本(或股本)                                    580,914,800.00                          580,914,800.00

     资本公积                                              348,611,062.03                          348,611,062.03

     减:库存股

     专项储备

     盈余公积                                              247,742,357.39                          247,742,357.39

     一般风险准备

     未分配利润                                           2,074,540,740.30                        1,900,142,349.33

     外币报表折算差额

归属于母公司所有者权益合计                                3,251,808,959.72                        3,077,410,568.75

     少数股东权益                                          232,261,670.39                          233,355,204.59

所有者权益(或股东权益)合计                              3,484,070,630.11                        3,310,765,773.34

负债和所有者权益(或股东权益)总
                                                          3,711,645,711.45                        3,643,315,938.55



法定代表人:安康                     主管会计工作负责人:谢军民                        会计机构负责人:王建体


2、母公司资产负债表

编制单位:华兰生物工程股份有限公司
                                                                                                          单位:元

                  项目                         期末余额                                期初余额


                                                                                                                 11
                                  华兰生物工程股份有限公司 2014 年第一季度报告全文


流动资产:

    货币资金                  424,322,978.91                        690,546,554.50

    交易性金融资产

    应收票据                   33,349,221.66                         23,436,200.00

    应收账款                   72,656,542.64                         55,034,074.75

    预付款项                   77,199,148.08                         45,515,855.68

    应收利息

    应收股利

    其他应收款                 77,396,348.48                        110,933,905.48

    存货                      195,502,223.37                        203,202,794.70

    一年内到期的非流动资产

    其他流动资产              680,000,000.00                        295,000,000.00

流动资产合计                 1,560,426,463.14                     1,423,669,385.11

非流动资产:

    可供出售金融资产

    持有至到期投资

    长期应收款                  5,379,060.00                          5,379,060.00

    长期股权投资              642,688,228.46                        642,961,299.81

    投资性房地产

    固定资产                  207,350,726.51                        213,083,308.47

    在建工程                  187,085,188.70                        173,308,464.61

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                   64,396,710.20                         65,026,217.09

    开发支出

    商誉

    长期待摊费用                3,328,883.00                          3,444,439.00

    递延所得税资产              3,489,703.36                          3,489,703.36

    其他非流动资产            100,000,000.00                        100,000,000.00

非流动资产合计               1,213,718,500.23                     1,206,692,492.34

资产总计                     2,774,144,963.37                     2,630,361,877.45

流动负债:



                                                                                12
                                        华兰生物工程股份有限公司 2014 年第一季度报告全文


    短期借款

    交易性金融负债

    应付票据

    应付账款                         64,750,544.02                         63,485,898.37

    预收款项                           2,017,811.00                         3,500,858.00

    应付职工薪酬                        314,470.70                           156,336.00

    应交税费                         31,700,773.58                         21,123,726.59

    应付利息

    应付股利

    其他应付款                          732,332.27                           276,771.90

    一年内到期的非流动负债

    其他流动负债

流动负债合计                         99,515,931.57                         88,543,590.86

非流动负债:

    长期借款

    应付债券

    长期应付款

    专项应付款

    预计负债

    递延所得税负债

    其他非流动负债

非流动负债合计

负债合计                             99,515,931.57                         88,543,590.86

所有者权益(或股东权益):

    实收资本(或股本)              580,914,800.00                        580,914,800.00

    资本公积                        357,358,859.54                        357,358,859.54

    减:库存股

    专项储备

    盈余公积                        247,742,357.39                        247,742,357.39

    一般风险准备

    未分配利润                     1,488,613,014.87                     1,355,802,269.66

    外币报表折算差额

所有者权益(或股东权益)合计       2,674,629,031.80                     2,541,818,286.59

负债和所有者权益(或股东权益)总   2,774,144,963.37                     2,630,361,877.45



                                                                                      13
                                                                华兰生物工程股份有限公司 2014 年第一季度报告全文





法定代表人:安康                        主管会计工作负责人:谢军民                      会计机构负责人:王建体


3、合并利润表

编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元

                 项目                             本期金额                              上期金额

一、营业总收入                                               278,440,387.76                        292,469,257.21

       其中:营业收入                                        278,440,387.76                        292,469,257.21

            利息收入

            已赚保费

            手续费及佣金收入

二、营业总成本                                               118,018,874.60                        149,029,483.86

       其中:营业成本                                         76,494,294.82                        124,574,087.23

            利息支出

            手续费及佣金支出

            退保金

            赔付支出净额

            提取保险合同准备金净额

            保单红利支出

            分保费用

            营业税金及附加                                     2,361,847.75                          1,679,910.73

            销售费用                                           5,865,175.68                          2,717,503.73

            管理费用                                          40,348,125.24                         30,886,927.64

            财务费用                                          -7,050,568.89                        -10,828,945.47

            资产减值损失

       加:公允价值变动收益(损失以
“-”号填列)

            投资收益(损失以“-”号
                                                              13,072,468.31                          4,293,655.71
填列)

            其中:对联营企业和合营
                                                                -273,071.35
企业的投资收益

            汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)                           173,493,981.47                        147,733,429.06


                                                                                                               14
                                                              华兰生物工程股份有限公司 2014 年第一季度报告全文


       加:营业外收入                                       34,882,136.34                           371,759.43

       减:营业外支出                                           83,222.37                           235,564.15

            其中:非流动资产处置损
                                                                 8,321.50                              4,197.20


四、利润总额(亏损总额以“-”号填
                                                           208,292,895.44                        147,869,624.34
列)

       减:所得税费用                                       34,988,038.67                         16,314,509.51

五、净利润(净亏损以“-”号填列)                         173,304,856.77                        131,555,114.83

       其中:被合并方在合并前实现的
净利润

       归属于母公司所有者的净利润                          174,398,390.97                        130,990,154.36

       少数股东损益                                         -1,093,534.20                           564,960.47

六、每股收益:                                     --                                    --

       (一)基本每股收益                                          0.3002                               0.2273

       (二)稀释每股收益                                          0.3002                               0.2273

七、其他综合收益

八、综合收益总额                                           173,304,856.77                        131,555,114.83

       归属于母公司所有者的综合收益
                                                           174,398,390.97                        130,990,154.36
总额

       归属于少数股东的综合收益总额                         -1,093,534.20                           564,960.47


法定代表人:安康                      主管会计工作负责人:谢军民                      会计机构负责人:王建体


4、母公司利润表

编制单位:华兰生物工程股份有限公司
                                                                                                       单位:元

                 项目                           本期金额                              上期金额

一、营业收入                                               190,051,057.50                        164,417,852.41

       减:营业成本                                         67,956,603.30                         62,190,987.27

           营业税金及附加                                    1,602,733.89                          1,317,197.81

           销售费用                                          1,530,045.03                            135,711.47

           管理费用                                         12,202,401.92                          9,190,286.42

           财务费用                                         -8,818,929.88                        -10,817,263.15

           资产减值损失

       加:公允价值变动收益(损失以
“-”号填列)


                                                                                                             15
                                                                华兰生物工程股份有限公司 2014 年第一季度报告全文


           投资收益(损失以“-”号填
                                                               6,680,524.54                           869,041.10
列)

           其中:对联营企业和合营企
                                                                -273,071.35
业的投资收益

二、营业利润(亏损以“-”号填列)                           122,258,727.78                        103,269,973.69

       加:营业外收入                                         34,045,299.33                             10,000.00

       减:营业外支出                                              7,902.50                              4,397.20

           其中:非流动资产处置损失                                7,902.50                              4,197.20

三、利润总额(亏损总额以“-”号填
                                                             156,296,124.61                        103,275,576.49
列)

       减:所得税费用                                         23,485,379.40                         15,491,336.48

四、净利润(净亏损以“-”号填列)                           132,810,745.21                         87,784,240.01

五、每股收益:                                       --                                    --

       (一)基本每股收益

       (二)稀释每股收益

六、其他综合收益

七、综合收益总额                                             132,810,745.21                         87,784,240.01


法定代表人:安康                        主管会计工作负责人:谢军民                      会计机构负责人:王建体


5、合并现金流量表

编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元

                 项目                             本期金额                              上期金额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                          294,745,904.59                        263,780,295.15

       客户存款和同业存放款项净增加


       向中央银行借款净增加额

       向其他金融机构拆入资金净增加


       收到原保险合同保费取得的现金

       收到再保险业务现金净额

       保户储金及投资款净增加额

       处置交易性金融资产净增加额

       收取利息、手续费及佣金的现金


                                                                                                               16
                                        华兰生物工程股份有限公司 2014 年第一季度报告全文


     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还

     收到其他与经营活动有关的现金    47,265,539.91                         36,715,449.81

经营活动现金流入小计                342,011,444.50                        300,495,744.96

     购买商品、接受劳务支付的现金   134,744,581.86                         96,183,263.88

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                     33,431,430.79                         30,858,022.67


     支付的各项税费                  45,775,322.45                         35,283,507.90

     支付其他与经营活动有关的现金    24,070,542.43                         26,221,504.56

经营活动现金流出小计                238,021,877.53                        188,546,299.01

经营活动产生的现金流量净额          103,989,566.97                        111,949,445.95

二、投资活动产生的现金流量:

     收回投资收到的现金             342,000,000.00                        342,000,000.00

     取得投资收益所收到的现金        13,345,539.66                          4,293,655.71

     处置固定资产、无形资产和其他
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金

投资活动现金流入小计                355,345,539.66                        346,293,655.71

     购建固定资产、无形资产和其他
                                     18,036,677.79                         43,111,540.73
长期资产支付的现金

     投资支付的现金                 627,000,000.00                        397,000,000.00

     质押贷款净增加额

     取得子公司及其他营业单位支付
的现金净额

     支付其他与投资活动有关的现金

投资活动现金流出小计                645,036,677.79                        440,111,540.73

投资活动产生的现金流量净额          -289,691,138.13                       -93,817,885.02


                                                                                      17
                                                                华兰生物工程股份有限公司 2014 年第一季度报告全文


三、筹资活动产生的现金流量:

       吸收投资收到的现金

       其中:子公司吸收少数股东投资
收到的现金

       取得借款收到的现金                                                                          140,000,000.00

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计                                                                               140,000,000.00

       偿还债务支付的现金                                    90,000,000.00

       分配股利、利润或偿付利息支付
                                                              1,245,000.00                           1,229,898.62
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现金

筹资活动现金流出小计                                         91,245,000.00                           1,229,898.62

筹资活动产生的现金流量净额                                   -91,245,000.00                        138,770,101.38

四、汇率变动对现金及现金等价物的
                                                                 33,461.51                             -67,202.98
影响

五、现金及现金等价物净增加额                               -276,913,109.65                         156,834,459.33

       加:期初现金及现金等价物余额                        1,027,260,672.95                        744,501,536.95

六、期末现金及现金等价物余额                                750,347,563.30                         901,335,996.28


法定代表人:安康                      主管会计工作负责人:谢军民                        会计机构负责人:王建体


6、母公司现金流量表

编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元

                 项目                           本期金额                                上期金额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                         172,435,232.85                         200,274,950.54

       收到的税费返还

       收到其他与经营活动有关的现金                          48,878,931.46                          13,558,060.40

经营活动现金流入小计                                        221,314,164.31                         213,833,010.94

       购买商品、接受劳务支付的现金                          84,652,084.70                          54,744,878.84

       支付给职工以及为职工支付的现
                                                              9,324,770.72                           9,450,046.47



                                                                                                               18
                                          华兰生物工程股份有限公司 2014 年第一季度报告全文


       支付的各项税费                  26,559,058.93                         23,964,437.98

       支付其他与经营活动有关的现金      9,886,822.21                        10,854,865.60

经营活动现金流出小计                  130,422,736.56                         99,014,228.89

经营活动产生的现金流量净额             90,891,427.75                        114,818,782.05

二、投资活动产生的现金流量:

       收回投资收到的现金             150,000,000.00                        250,000,000.00

       取得投资收益所收到的现金          6,953,595.89                          869,041.10

       处置固定资产、无形资产和其他
长期资产收回的现金净额

       处置子公司及其他营业单位收到
的现金净额

       收到其他与投资活动有关的现金

投资活动现金流入小计                  156,953,595.89                        250,869,041.10

       购建固定资产、无形资产和其他
                                       11,472,108.39                         28,678,147.70
长期资产支付的现金

       投资支付的现金                 500,000,000.00

       取得子公司及其他营业单位支付
的现金净额

       支付其他与投资活动有关的现金                                          80,000,000.00

投资活动现金流出小计                  511,472,108.39                        108,678,147.70

投资活动产生的现金流量净额            -354,518,512.50                       142,190,893.40

三、筹资活动产生的现金流量:

       吸收投资收到的现金

       取得借款收到的现金

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计

       偿还债务支付的现金

       分配股利、利润或偿付利息支付
的现金

       支付其他与筹资活动有关的现金

筹资活动现金流出小计

筹资活动产生的现金流量净额

四、汇率变动对现金及现金等价物的
                                           33,461.51                            -67,191.14
影响

五、现金及现金等价物净增加额          -263,593,623.24                       256,942,484.31


                                                                                        19
                                                           华兰生物工程股份有限公司 2014 年第一季度报告全文


     加:期初现金及现金等价物余额                      682,699,844.20                            485,366,547.51

六、期末现金及现金等价物余额                           419,106,220.96                            742,309,031.82


法定代表人:安康                    主管会计工作负责人:谢军民                      会计机构负责人:王建体


二、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                                                        华兰生物工程股份有限公司


                                                                              董事长:安康


                                                                            2014 年 4 月 25 日




                                                                                                             20
数据加载中...
prevnext
手机查看股票